PharmaShots | Incisive News in 3 Shots

Subscribe Now

Otsuka

Otsuka and Lundbeck Receive the EC’s Approval for Rxulti to Treat Schizophrenia in Adolescents

Otsuka and Lundbeck Receive the EC’s Approval for Rxulti to Treat Schizophrenia in Adolescents

March 13, 2025

Otsuka and Astex Receive EC’s Approval for Inaqovi (decitabine and cedazuridine) to Treat Newly Diagnosed Acute Myeloid Leukaemia

Otsuka and Astex Receive EC’s Approval for Inaqovi (decitabine and cedazuridine) to Treat Newly Diagnosed Acute Myeloid Leukaemia

September 19, 2023

Otsuka Entered into a Multi-Target Collaboration with ShapeTX to Develop Novel AAV Gene Therapies for Ocular Diseases

Otsuka Entered into a Multi-Target Collaboration with ShapeTX to Develop Novel AAV Gene Therapies for Ocular Diseases

September 8, 2023

Otsuka and Lundbeck Receive the US FDA’s Approval for Rexulti (brexpiprazole) sNDA to Treat Agitation Associated with Dementia Due to Alzheimer’s Disease

Otsuka and Lundbeck Receive the US FDA’s Approval for Rexulti (brexpiprazole) sNDA to Treat Agitation Associated with Dementia Due...

May 12, 2023

Otsuka’s Lupkynis (voclosporin) Receives NICE Recommendation for the Treatment of Active Lupus Nephritis

Otsuka’s Lupkynis (voclosporin) Receives NICE Recommendation for the Treatment of Active Lupus Nephritis

May 4, 2023

Otsuka and Lundbeck’s Abilify Asimtufii (aripiprazole) Receive the US FDA’s Approval as First Long-Acting Injectable for Schizophrenia or Bipolar I Disorder

Otsuka and Lundbeck’s Abilify Asimtufii (aripiprazole) Receive the US FDA’s Approval as First Long-Acting Injectable for Schizophr...

April 27, 2023

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us